Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT00818662
Show Display Options
Rank Status Study
1 Completed
Has Results
A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease
Condition: Alzheimer´s Disease
Interventions: Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg;   Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg;   Biological: Placebo solution: Human Albumin 0.25% - 4 mL/kg;   Biological: Placebo solution: Human Albumin 0.25% - 2 mL/kg

Indicates status has not been verified in more than two years